Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: BioHarvest Sciences Inc.

Market Cap 73.9M 64.43M 59.67M 55.86M 105M 6.97B 105M 708M 274M 3.43B 277M 271M 11.92B P/E 2026 *
-8x
P/E 2027 * -19.8x
Enterprise Value 73.9M 64.43M 59.67M 55.86M 105M 6.97B 105M 708M 274M 3.43B 277M 271M 11.92B EV / Sales 2026 *
1.72x
EV / Sales 2027 * 1.25x
Free-Float
85.23%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 68 2026-04-28
Director of Finance/CFO - 2024-10-27
Chief Operating Officer 65 2023-04-18
Director TitleAgeSince
Chairman 68 2018-09-26
Director/Board Member 67 2018-09-26
Director/Board Member 84 2019-02-06
Change 5-day change 1-year change 3-year change Capi.($)
+6.06%-2.94% - - 73.9M
-0.98%-4.29%-11.99%-8.12% 12.77B
-1.84%-5.81%-34.70%-57.37% 4.76B
-3.47%-9.51%-12.64%-5.68% 4.34B
+0.29%-1.20%+15.86%-17.11% 3.8B
+0.47%-4.39%+7.98%-42.85% 3.71B
-1.30%-4.43%-5.37%-9.66% 3.53B
-0.07%-2.22%-9.10%-2.08% 3.11B
-0.71%+0.39%-4.08%-25.54% 2.38B
-1.61%-3.41%-11.79%+28.81% 1.67B
Average -0.32%-3.87%-7.32%-15.51% 4.45B
Weighted average by Cap. -1.05%-4.29%-8.99%-16.93%

Financials

2026 *2027 *
Net sales 42.89M 37.4M 34.63M 32.42M 60.81M 4.05B 61.17M 411M 159M 1.99B 161M 158M 6.92B 58.96M 51.4M 47.61M 44.57M 83.58M 5.56B 84.09M 565M 219M 2.74B 221M 217M 9.51B
Net income -9.27M -8.08M -7.48M -7M -13.14M -874M -13.22M -88.76M -34.4M -430M -34.78M -34.03M -1.49B -3.77M -3.29M -3.05M -2.85M -5.35M -356M -5.38M -36.15M -14.01M -175M -14.16M -13.86M -609M
Net Debt - -
Logo BioHarvest Sciences Inc.
BioHarvest Sciences Inc. is a botanical synthesis company. The Company leverages its patented technology process to grow plant-based molecules, without the need to grow the underlying plant. It is leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions within two business verticals: as a contract development and production organization on behalf of customers seeking complex molecules, and as a creator of nutraceutical health and wellness products, which include dietary supplements. Its segments include Nutraceuticals and Pharmaceuticals. VINIA is a red grape cell-based supplement, which is a commercial nutraceutical product derived from the Botanical Synthesis platform and is clinically proven to improve blood flow, which enhances physical energy and mental alertness. VINIA contains multiple polyphenols, including Piceid Resveratrol, which is 25x more soluble in water than regular resveratrol.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
3.260USD
Average target price
12.75USD
Spread / Average Target
+291.10%

Quarterly revenue - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!